Cite
HARVARD Citation
King, A. et al. (n.d.). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. Annals of pharmacotherapy. pp. 410-416. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
King, A. et al. (n.d.). Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies. Annals of pharmacotherapy. pp. 410-416. [Online].